Our study, which included a large cohort of 2173 invasive breast cancer patients, has shown a high concordance rate for ER, PR, and HER2 status between CNB and OEB, but a fair agreement for Ki67 and molecular subtype testing. This evidence concerns the gene ERBB2 and invasive breast carcinoma.